The pivotal Phase 2 trial (NCT04881760), published in The New England Journal of Medicine (Jastreboff et al., 2023), enrolled 338 adults with BMI 30 or higher
Cagrilintide Synonyms / Designations: Cagrilintide, AM833, Long-acting amylin analogue, Dual amylin receptor agonist CAS Number: 1415456-99-3 Molecular Formula: C194H312N54O59S2 Molecular Weight: 4409.01 g/mol Peptide Classification: Synthetic long-acting amylin analogue Purity: 99 % (HPLC, typical) Appearance: White to off-white lyophilised powder Pack Size: Research pack size (varies) Storage: Desiccated, protected from light, stored at 20 C Solubility: Soluble in sterile water and buffered aqueous solutions Description & Mechanism Cagrilintide is a synthetic long-acting analogue of the endogenous peptide hormone amylin, developed for experimental investigation of amylin receptor signalling and metabolic regulation
Moreno, Food Science and Technology Department (CSIC), Spain Reviewed by Antonio Jos Ruiz-Alcaraz, University of Murcia, Spain Elizabeth H
Randomized pilot study
Pentadecapeptide BPC 157 and the dopamine system
.png)
